CN Patent
CN113135896B — 作为ret抑制剂的甲基吡唑类衍生物
Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2024-12-06 · 1y expired
What this patent protects
本申请涉及作为RET抑制剂的甲基吡唑类衍生物,具体涉及式(I)所示化合物、其立体异构体及其药学上可接受的盐,其制备方法及其药物组合物。本申请所述式(I)化合物可用于预防或治疗由异常RET活性介导的疾病。
USPTO Abstract
本申请涉及作为RET抑制剂的甲基吡唑类衍生物,具体涉及式(I)所示化合物、其立体异构体及其药学上可接受的盐,其制备方法及其药物组合物。本申请所述式(I)化合物可用于预防或治疗由异常RET活性介导的疾病。
Drugs covered by this patent
- Gavreto (PRALSETINIB) · Rigel Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.